Anticipating NRAS Resistance
How researchers are unraveling the mystery of melanoma drug resistance
William Aryitey |
Every medical treatment is a tradeoff between benefit and side effect – and part of any physician’s job is to determine whether or not the downsides to a given treatment are a worthwhile price to pay for its potential health benefits. One factor in the therapeutic equation is resistance: what good is a treatment if the patient’s disease can resist its effects?
Establishing whether or not a disease exhibits resistance mechanisms is especially important when it involves patients whose illnesses could be fatal if left untreated. A team at The University of Texas MD Anderson Cancer Center, led by Lawrence Kwong, decided to tackle this issue in patients with NRAS melanoma. To learn more, we spoke with Lawrence Kwong, Assistant Professor in the Department of Translational Molecular Pathology at MD Anderson.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!